Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Share-based Compensation: 2014-2024

Historic Share-based Compensation for Protagonist Therapeutics (PTGX) over the last 11 years, with Dec 2024 value amounting to $37.6 million.

  • Protagonist Therapeutics' Share-based Compensation rose 3.88% to $10.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $44.4 million, marking a year-over-year increase of 26.54%. This contributed to the annual value of $37.6 million for FY2024, which is 28.20% up from last year.
  • Latest data reveals that Protagonist Therapeutics reported Share-based Compensation of $37.6 million as of FY2024, which was up 28.20% from $29.3 million recorded in FY2023.
  • Over the past 5 years, Protagonist Therapeutics' Share-based Compensation peaked at $37.6 million during FY2024, and registered a low of $7.9 million during FY2020.
  • For the 3-year period, Protagonist Therapeutics' Share-based Compensation averaged around $30.3 million, with its median value being $29.3 million (2023).
  • As far as peak fluctuations go, Protagonist Therapeutics' Share-based Compensation decreased by 5.44% in 2020, and later skyrocketed by 107.56% in 2021.
  • Protagonist Therapeutics' Share-based Compensation (Yearly) stood at $7.9 million in 2020, then spiked by 107.56% to $16.4 million in 2021, then soared by 47.62% to $24.2 million in 2022, then climbed by 21.04% to $29.3 million in 2023, then rose by 28.20% to $37.6 million in 2024.